Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q2

2160.TEDINET S100ROIG
Period2023-01-01 → 2023-06-30
Filed2023-08-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥14.1bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥9.9bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Revenue¥17.4bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥8.2bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.2bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Operating income¥5.5bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥5.1bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Operating income¥1.0bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥526m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Profit before tax¥5.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥5.2bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Profit before tax¥768m2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥790m2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥443m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.7bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.7bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥389m2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥676m2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥325m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.0bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥4.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Net income−¥868m2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥198m2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥126m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Total assets¥45.1bnat 2023-06-30Cons.Assets IFRS
Total assets¥33.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥35.3bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥20.3bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥14.1bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥24.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥21.8bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥23.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.0bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥14.1bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.5bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥872m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥393m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥389m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.6bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥4.1bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.5bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥3.9bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥646m2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥267m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥34.932023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥34.992023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥8.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥14.252022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥6.862022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥34.812023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥34.882023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.112022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥14.182022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥6.832022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio51.0%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.5%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥23m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-06-30¥1.4bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-06-30¥1.3bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-06-30¥512m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-06-30¥5.0bn
—segment totalrevenue2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥23m
—segment totalsegment profit2023-01-01 → 2023-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-06-30¥526m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-06-30¥479m
—segment totalrevenue2022-01-01 → 2022-06-30¥8.2bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥8.2bn
—segment totalsegment profit2022-01-01 → 2022-06-30¥1.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 670
ItemContextValueUnit
Profit loss IFRSCurrentYTDDuration4014074000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration676446000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration1658805000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration-478528000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration2355269000JPY
Basic earnings loss per share IFRSPrior1YTDDuration14.25
Basic earnings loss per share IFRSCurrentYTDDuration34.93
Diluted earnings loss per share IFRSPrior1YTDDuration14.18
Diluted earnings loss per share IFRSCurrentYTDDuration34.81
Revenue IFRSPrior1QuarterDuration4221327000JPY
Revenue IFRSCurrentQuarterDuration9890409000JPY
Cost of sales IFRSPrior1QuarterDuration585213000JPY
Cost of sales IFRSCurrentQuarterDuration767856000JPY
Gross profit IFRSPrior1QuarterDuration3636114000JPY
Gross profit IFRSCurrentQuarterDuration9122552000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration2307425000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration3532820000JPY
Research and development expenditure recognized as expense during period IFRSPrior1QuarterDuration620669000JPY
Research and development expenditure recognized as expense during period IFRSCurrentQuarterDuration617410000JPY
Other income IFRSPrior1QuarterDuration14751000JPY
Other income IFRSCurrentQuarterDuration153965000JPY
Other expenses IFRSPrior1QuarterDuration197029000JPY
Other expenses IFRSCurrentQuarterDuration47410000JPY
Operating profit loss IFRSPrior1QuarterDuration525741000JPY
Operating profit loss IFRSCurrentQuarterDuration5078877000JPY
Finance income IFRSPrior1QuarterDuration121102000JPY
Finance income IFRSCurrentQuarterDuration257195000JPY
Finance costs IFRSPrior1QuarterDuration203881000JPY
Finance costs IFRSCurrentQuarterDuration299438000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration－JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration146262000JPY
Profit loss before tax IFRSPrior1QuarterDuration442962000JPY
Profit loss before tax IFRSCurrentQuarterDuration5182896000JPY
Income tax expense IFRSPrior1QuarterDuration317332000JPY
Income tax expense IFRSCurrentQuarterDuration827076000JPY
Profit loss IFRSPrior1QuarterDuration125629000JPY
Profit loss IFRSCurrentQuarterDuration4355820000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration325432000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration1661679000JPY
Profit loss attributable to non controlling interests IFRSPrior1QuarterDuration-199802000JPY
Profit loss attributable to non controlling interests IFRSCurrentQuarterDuration2694140000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration6.86
Basic earnings loss per share IFRSCurrentQuarterDuration34.99
Diluted earnings loss per share IFRSPrior1QuarterDuration6.83
Diluted earnings loss per share IFRSCurrentQuarterDuration34.88
Profit loss IFRSPrior1YTDDuration197918000JPY
Profit loss IFRSCurrentYTDDuration4014074000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration2136618000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration897349000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass